Feasibility of combined treatment with enalapril and candesartan in advanced chronic kidney disease
Open Access
- 9 November 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 25 (3) , 842-847
Abstract
Background. Dual blockade of the renin–angiotensin system (RAS) has been claimed to have a specific renal protective effect in chronic kidney disease (CKD). The present short-term study reports on the feasibility of dual blockade in a consecutive group of patients with CKD stage 3–5. Methods. Forty-seven CKD patients, mean age 59 years, with mean estimated glomerular filtration rate (GFR) 26 ml/min/1.73 m² (range 13–49) and blood pressure (BP) 133/78 mmHg, were block randomized in an open study to 16 weeks of monotherapy with increasing doses of RAS blockade aiming at enalapril 20 mg o.d. or candesartan 16 mg o.d. Thereafter, the complementary drug was added in incremental doses over a period of 5 weeks aiming at combined enalapril 20 mg and candesartan 16 mg for 3 weeks. Seventy-five percent of the patients were known to be RAS blockade tolerant. Blood samples and BP were measured every 2–3 weeks. Doses of study medication were reduced in case of hyperkalemia >5.5 mmol/l, a sustained rise in p-creatinine >30% or symptomatic hypotension. Results. Twenty-one patients (45%) did not tolerate dual blockade in aimed dosages due to unacceptable p-creatinine increase (n = 12, including two study withdrawals), hypotension (n = 6), general discomfort (n = 2) or unmanageable hyperkalemia (n = 1). Hyperkalemia >5.5 mmol/l was seen in seven patients (15%). The reduced-dose group had baseline lower eGFR and diastolic BP. Conclusions. Forty-five percent of CKD stage 3–5 patients did not tolerate dual RAS blockade with 20 mg enalapril and 16 mg candesartan daily, primarily due to loss of renal function or hypotension. Hyperkalemia could be managed in most patients. Caution is recommended when giving this treatment to patients with advanced CKD.Keywords
This publication has 29 references indexed in Scilit:
- Dual Renin-Angiotensin System Blockade and Kidney DiseaseJACC, 2009
- Design of Combination Angiotensin Receptor Blocker and Angiotensin-Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D)Clinical Journal of the American Society of Nephrology, 2009
- Dual Blockade of the Renin-Angiotensin System for Cardiorenal Protection: An UpdateAmerican Journal of Kidney Diseases, 2009
- The Sudden Demise of Dual Renin-Angiotensin System Blockade or the Soft Science of the Surrogate End PointJACC, 2009
- Role of Remission Clinics in the Longitudinal Treatment of CKDJournal of the American Society of Nephrology, 2008
- Untoward effects of chronic dual renin-angiotensin system blockade: influence of previous chronic renal failureInternational Journal Of Clinical Practice, 2006
- Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuriaNephrology Dialysis Transplantation, 2002
- A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart FailureNew England Journal of Medicine, 2001
- High serum enalaprilat in chronic renal failureJournal of the Renin-Angiotensin-Aldosterone System, 2001
- Initial Effect of Enalapril on Kidney Function in Patients with Moderate to Severe Chronic NephropathyScandinavian Journal of Urology and Nephrology, 1990